Page last updated: 2024-10-28

fasudil and Schizophrenia

fasudil has been researched along with Schizophrenia in 3 studies

fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.

Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.

Research Excerpts

ExcerptRelevanceReference
"Current antipsychotics used to treat schizophrenia have associated problems, including serious side effects and treatment resistance."5.72Antipsychotic-like effects of fasudil, a Rho-kinase inhibitor, in a pharmacologic animal model of schizophrenia. ( Kaibuchi, K; Liao, J; Liu, Y; Miyagawa, Y; Mizoguchi, H; Nagai, T; Ozaki, N; Sawahata, M; Sobue, A; Takase, S; Tanaka, R; Yamada, K, 2022)
"Current antipsychotics used to treat schizophrenia have associated problems, including serious side effects and treatment resistance."1.72Antipsychotic-like effects of fasudil, a Rho-kinase inhibitor, in a pharmacologic animal model of schizophrenia. ( Kaibuchi, K; Liao, J; Liu, Y; Miyagawa, Y; Mizoguchi, H; Nagai, T; Ozaki, N; Sawahata, M; Sobue, A; Takase, S; Tanaka, R; Yamada, K, 2022)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's3 (100.00)2.80

Authors

AuthorsStudies
Takase, S1
Liao, J5
Liu, Y2
Tanaka, R4
Miyagawa, Y1
Sawahata, M2
Sobue, A1
Mizoguchi, H5
Nagai, T5
Kaibuchi, K5
Ozaki, N5
Yamada, K5
Hada, K3
Mori, D3
Matsuzaki, T3
Nabeshima, T4
Dong, G1
Zhu, W1
Wulaer, B1

Other Studies

3 other studies available for fasudil and Schizophrenia

ArticleYear
Antipsychotic-like effects of fasudil, a Rho-kinase inhibitor, in a pharmacologic animal model of schizophrenia.
    European journal of pharmacology, 2022, Sep-15, Volume: 931

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Antipsychotic Agents; Disease Models, Animal

2022
Inhibition of Rho-kinase ameliorates decreased spine density in the medial prefrontal cortex and methamphetamine-induced cognitive dysfunction in mice carrying schizophrenia-associated mutations of the Arhgap10 gene.
    Pharmacological research, 2023, Volume: 187

    Topics: Animals; Cognitive Dysfunction; Mice; Mutation; Prefrontal Cortex; Protein Kinase Inhibitors; rho-As

2023
Inhibition of Rho-kinase ameliorates decreased spine density in the medial prefrontal cortex and methamphetamine-induced cognitive dysfunction in mice carrying schizophrenia-associated mutations of the Arhgap10 gene.
    Pharmacological research, 2023, Volume: 187

    Topics: Animals; Cognitive Dysfunction; Mice; Mutation; Prefrontal Cortex; Protein Kinase Inhibitors; rho-As

2023
Inhibition of Rho-kinase ameliorates decreased spine density in the medial prefrontal cortex and methamphetamine-induced cognitive dysfunction in mice carrying schizophrenia-associated mutations of the Arhgap10 gene.
    Pharmacological research, 2023, Volume: 187

    Topics: Animals; Cognitive Dysfunction; Mice; Mutation; Prefrontal Cortex; Protein Kinase Inhibitors; rho-As

2023
Inhibition of Rho-kinase ameliorates decreased spine density in the medial prefrontal cortex and methamphetamine-induced cognitive dysfunction in mice carrying schizophrenia-associated mutations of the Arhgap10 gene.
    Pharmacological research, 2023, Volume: 187

    Topics: Animals; Cognitive Dysfunction; Mice; Mutation; Prefrontal Cortex; Protein Kinase Inhibitors; rho-As

2023
Rho kinase inhibitors ameliorate cognitive impairment in a male mouse model of methamphetamine-induced schizophrenia.
    Pharmacological research, 2023, Volume: 194

    Topics: Animals; Clozapine; Cognitive Dysfunction; Haloperidol; Male; Methamphetamine; Mice; Monomeric GTP-B

2023